Scientists from MD Anderson have sat on boards of previous companies that had mRNA molecules in Phase I and II studies that failed and said companies now do not exist due to bankruptcy.
SB i believe has a few products (potential), so some diversification is a positive here.
Not many of the cold hard facts can be known about their product, outside of human clinical trials, imo.
This includes the level and variation of what sort of cytokinin activity will result (toxicity), once administered in the human body.
News 
Market Data 
Discover 
AI
